from24/7 Wall St.
6 days agoMedicine
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
Oppenheimer initiated Outperform coverage of Ocugen with a $10 price target, betting on OCU400's potential 2027 approval as a gene-agnostic treatment for retinitis pigmentosa affecting a broad patient population.
